These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 25706703)

  • 21. Targeted therapies: Is there a role for rituximab in nephrotic syndrome?
    Feehally J
    Nat Rev Nephrol; 2014 May; 10(5):245-7. PubMed ID: 24614409
    [No Abstract]   [Full Text] [Related]  

  • 22. Cyclophosphamide and rituximab in frequently relapsing/steroid-dependent nephrotic syndrome.
    Webb H; Jaureguiberry G; Dufek S; Tullus K; Bockenhauer D
    Pediatr Nephrol; 2016 Apr; 31(4):589-94. PubMed ID: 26525199
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rituximab in steroid-dependent idiopathic nephrotic syndrome in childhood--follow-up after CD19 recovery.
    Sellier-Leclerc AL; Baudouin V; Kwon T; Macher MA; Guérin V; Lapillonne H; Deschênes G; Ulinski T
    Nephrol Dial Transplant; 2012 Mar; 27(3):1083-9. PubMed ID: 21810762
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Idiopathic nephrotic syndrome in children: from corticosteroids to rituximab].
    Deschênes G
    Arch Pediatr; 2011 Aug; 18(8):843-5. PubMed ID: 21719260
    [No Abstract]   [Full Text] [Related]  

  • 25. [Beneficial effects of rituximab in the treatment of refractory nephrotic syndrome].
    Imai E
    Nihon Jinzo Gakkai Shi; 2012; 54(5):593-7. PubMed ID: 22991838
    [No Abstract]   [Full Text] [Related]  

  • 26. Re-treatment with high-dose prednisolone after rituximab infusion for childhood-onset steroid-resistant nephrotic syndrome.
    Fujinaga S; Hara T
    Pediatr Nephrol; 2014 Jul; 29(7):1291-2. PubMed ID: 24633445
    [No Abstract]   [Full Text] [Related]  

  • 27. [Immunosuppressive therapies for refractory nephrotic syndrome].
    Mitarai T
    Nihon Jinzo Gakkai Shi; 2010; 52(7):924-7. PubMed ID: 21077342
    [No Abstract]   [Full Text] [Related]  

  • 28. [Controversial issues in the Giornale Italiano di Nefrologia: how to treat patients with focal segmental glomerular sclerosis].
    Passerini P; Scolari F; Frasca' GM; Leoni A; Venturelli C; Dallera N; Ravera S; Balestra E; Freddi P; Fanciulli E; D'Arezzo M; Sagripanti S
    G Ital Nefrol; 2009; 26(5):563-76. PubMed ID: 19802802
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ofatumumab for rituximab-resistant nephrotic syndrome.
    Basu B
    N Engl J Med; 2014 Mar; 370(13):1268-70. PubMed ID: 24670185
    [No Abstract]   [Full Text] [Related]  

  • 30. Difficulties in diagnosing severe Pneumocystis jiroveci pneumonia after rituximab therapy for steroid-dependent nephrotic syndrome.
    Czarniak P; Załuska-Leśniewska I; Zagożdżon I; Zurowska A
    Pediatr Nephrol; 2013 Jun; 28(6):987-8. PubMed ID: 23549855
    [No Abstract]   [Full Text] [Related]  

  • 31. Rituximab for childhood refractory nephrotic syndrome.
    Iijima K
    Pediatr Int; 2011 Oct; 53(5):617-621. PubMed ID: 21771179
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of rituximab in children with difficult-to-treat nephrotic syndrome.
    Sinha A; Bhatia D; Gulati A; Rawat M; Dinda AK; Hari P; Bagga A
    Nephrol Dial Transplant; 2015 Jan; 30(1):96-106. PubMed ID: 25121488
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rituximab for steroid-dependent nephrotic syndrome.
    Beco A; Castro-Ferreira I; Coentrao L; Neto R; Sampaio S; Pestana M
    Clin Nephrol; 2010 Oct; 74(4):308-10. PubMed ID: 20875384
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Repeated course of rituximab for treatment of nephrotic syndrome in patients with chronic GVHD.
    Mellon-Reppen S; Ratanatharathorn V; Cronin S; Uberti JP
    Bone Marrow Transplant; 2010 Dec; 45(12):1758-9. PubMed ID: 20383208
    [No Abstract]   [Full Text] [Related]  

  • 35. Critical evaluation of rituximab rescue in 27 patients with different types of kidney disease.
    Ganzemueller J; Hartmann B; Keller F; Stracke S
    Minerva Urol Nefrol; 2011 Dec; 63(4):263-72. PubMed ID: 21996981
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of rituximab treatment in children with primary glomerulonephritis.
    Zachwieja J; Silska M; Ostalska-Nowicka D; Soltysiak J; Lipkowska K; Blumczynski A; Musielak A
    J Nephrol; 2012; 25(6):1060-6. PubMed ID: 22322817
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term effect of rituximab in maintaining remission of recurrent and plasmapheresis-dependent nephrotic syndrome post-renal transplantation - case report.
    Grenda R; Jarmużek W; Piątosa B; Rubik J
    Pediatr Transplant; 2011 Sep; 15(6):E121-5. PubMed ID: 20331516
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rituximab in treatment of idiopathic glomerulopathy.
    El-Reshaid K; Sallam HT; Hakim AA; Al-Attiyah R
    Saudi J Kidney Dis Transpl; 2012 Sep; 23(5):973-8. PubMed ID: 22982909
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Advances in the treatment of adult nephrotic syndrome].
    Yokoyama H; Asaka M; Yamaya H; Wada T
    Nihon Jinzo Gakkai Shi; 2007; 49(2):108-12. PubMed ID: 17375618
    [No Abstract]   [Full Text] [Related]  

  • 40. Risk factors for early relapse during maintenance therapy after a single infusion of rituximab in children with steroid-dependent nephrotic syndrome.
    Fujinaga S; Hirano D
    Pediatr Nephrol; 2014 Mar; 29(3):491-2. PubMed ID: 24240472
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.